Glenmark reduces price of FabiFlu by 27 per cent in India
On Monday, Glenmark Pharmaceuticals, global research-led pharmaceutical company announced that it has begun post-marketing surveillance (PMS) study on Fabiflu to closely monitor the efficacy and safety of the medicine in 1,000 patients, who prescribed with the oral antiviral, as part of an open-label, multicentre, single-arm study.
The new price of the drug is Rs 75 per tab, which has been reduced by 27 per cent as against the earlier price of Rs 103 per tab. With higher yields and better scales, the company has gained benefits thus, making the price reduction possible. As both active pharmaceutical ingredients (APIs) and formulation of the drug are made at Glenmark’s facilities in India, the benefits are easily passed on to the patients in the country.
Glenmark has priced the drug lowest in India in comparison to the prices in other countries. The company hopes this price reduction will ensure the accessibility of the drug to all the patients across the country.
The share of Glenmark Pharmaceuticals Limited was trading at Rs 417.85 at 2.08 pm. Despite the announcement, it has declined by 2.07 per cent on BSE in today’s session. It has a 52-week high of Rs 572.7 and a 52-week low of Rs 168.